NAD+ IV Therapy for Addiction Recovery: What the Evidence Shows

Walk into a private detox or "brain restoration" clinic and you may be offered a treatment that sounds almost too good: a multi-day intravenous drip of NAD+ that is said to ease withdrawal, quiet cravings, and "reset" the addicted brain. It is marketed for alcohol, opioids, and stimulants alike, often as a centerpiece of a several-thousand-dollar recovery package. The pitch is compelling and the testimonials are vivid.

But addiction is a high-stakes, life-and-death condition, and that is exactly the situation where the gap between marketing and evidence matters most. This page lays out, honestly, what NAD+ IV therapy for addiction is claimed to do, what the human evidence actually shows (very little), and — most importantly — what does have strong evidence, so that nobody trades a proven treatment for an unproven drip.

If you or someone you love is in withdrawal or crisis, this is not the article to act on alone. Contact a physician or, in the US, the SAMHSA National Helpline (1-800-662-4357). Withdrawal from alcohol and benzodiazepines can be medically dangerous.

What clinics are actually selling

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell. It shuttles electrons through the reactions that turn food into cellular energy and also fuels DNA-repair enzymes and the sirtuins, so low NAD+ availability is genuinely linked to metabolic and mitochondrial dysfunction ¹. NAD+ also falls with age and metabolic stress in human tissue ². The addiction-recovery pitch extends that idea: the theory goes that chronic heavy substance use depletes NAD+ and disrupts the brain's dopamine "reward" circuitry, and that flooding the body with intravenous NAD+ replenishes the coenzyme, restores neurotransmitter balance, and thereby eases withdrawal and cravings.

In practice the protocol is an IV infusion of NAD+ — often 500–1,000 mg or more per day — run slowly over several hours because faster rates cause chest tightness, flushing, nausea, and cramping. Clinics typically recommend a course of consecutive daily infusions (commonly a week to ten days), frequently bundled with amino acids, vitamins, and counseling. It is sometimes branded as "BR+NAD," "NAD brain restoration," or "NAD detox."

The claimed mechanism vs. the absence of proof

The mechanism is not absurd on paper. NAD+ does sit at the center of cellular energy metabolism ¹, and the broad "reward deficiency" idea — that disrupted dopamine signaling underlies addictive behavior, and that restoring dopamine homeostasis could help — is a real line of research ⁵. The problem is the leap from that plausible biology to "therefore an IV NAD+ drip treats addiction in humans." That leap has essentially never been tested rigorously.

Start with a basic pharmacology problem. The only published human study that actually measured what happens to NAD+ in the body during an IV infusion was a 2019 pilot: over a 6-hour drip, free NAD+ was largely not detectable in the bloodstream for hours as the body metabolized it ⁶. That study measured the metabolome — not withdrawal, not cravings, not abstinence — and had no placebo arm. So even the "you're filling the brain's NAD+ tank" premise rests on shaky pharmacokinetics; we cover this in depth in our look at NAD+ IV therapy evidence and cost.

Now the clinical evidence for addiction specifically. It exists, but it is weak by design. The published reports are uncontrolled clinic case series — most prominently a pair of "fifty cases" descriptive annotations from the same research group reporting that NAD+-based infusions improved clinical outcomes and reduced psychiatric burden in people with substance use disorder ³⁴. Read honestly, these are observations from patients who chose (and paid for) the treatment, with no control group, no randomization, and no blinding — so there is no way to separate a genuine drug effect from placebo, the natural easing of acute withdrawal over days, the counseling and structure delivered alongside the drip, or simple reporting bias. They are hypothesis-generating at best, not proof.

What does not exist is the thing that would settle the question: a rigorous, randomized, placebo-controlled trial showing that IV NAD+ reduces withdrawal severity, cravings, or relapse. There isn't one. And we should be skeptical for a concrete reason beyond "no trial yet": even oral NAD+ precursors, which have real placebo-controlled trials, have a poor track record of converting a raised NAD+ biomarker into felt benefits. Nicotinamide riboside reliably lifted NAD+ in older adults with mild cognitive impairment yet left cognition unchanged ⁷, and it augmented the aged-muscle NAD+ metabolome without improving muscle function ⁸. If the routes with actual trials struggle to turn more NAD+ into measurable outcomes, an IV route with zero addiction outcome trials cannot honestly claim to fix the brain. We keep this "biomarker is not benefit" distinction central in our NAD+ therapy evidence pillar.

What actually works for addiction (don't trade this away)

This is the most important section, and it is where the honesty has to be loudest: there are treatments for addiction that are genuinely supported by large, controlled human trials. NAD+ IV therapy should never displace them.

• •Alcohol use disorder. FDA-approved medications — naltrexone and acamprosate — have a real evidence base. The landmark COMBINE randomized trial showed naltrexone (with medical management) improved drinking outcomes in alcohol-dependent patients ⁹, and a 2023 JAMA systematic review and meta-analysis confirmed that naltrexone and acamprosate reduce return to drinking ¹¹. These are proven, inexpensive, and widely available.
• •Opioid use disorder. Medications for opioid use disorder (MOUD) — buprenorphine and methadone — are the standard of care and save lives. A Cochrane systematic review found buprenorphine maintenance retains people in treatment and suppresses illicit opioid use versus placebo ¹⁰. These medications reduce overdose death; an unproven drip does not.
• •Behavioral treatment. Counseling, contingency management, and structured recovery support are core to every evidence-based program — and notably, they are often the part of a "NAD detox" package that is actually doing the work.

The danger of marketing NAD+ as a stand-alone "cure" or "reset" is that someone in a fragile moment chooses an expensive, unproven infusion instead of medication that is known to prevent relapse and death. At best, NAD+ IV therapy is an unproven adjunct delivered alongside real treatment. It is not a substitute for it, and any clinic implying otherwise is overselling.

Safety and the cost

The most reliable, documented effect of IV NAD+ is its infusion-reaction side effects: chest tightness or pressure, flushing, nausea, abdominal cramping, and lightheadedness when run too fast, which is why drips are slowed to hours ⁶. These are usually transient, but they are real, and there are the ordinary risks of any IV line — infection, vein irritation, and the need for genuine clinical oversight (which matters enormously in someone who is also withdrawing). For a route-by-route breakdown, see our guide to NAD+ side effects.

The cost is steep. Because NAD+ is not an FDA-approved treatment for addiction (or anything else), it is not covered by insurance, and a multi-day "brain restoration" course commonly runs several thousand dollars — frequently $5,000–$15,000 for a full program. By contrast, the medications with actual trial evidence for addiction cost a small fraction of that. Paying a premium price for the unproven option, while evidence-based medication sits on the shelf, is the core problem with this market.

The bottom line

The mechanism behind NAD+ for addiction recovery is plausible, and the cellular biology of NAD+ is real ¹⁵ — but plausibility is not proof. The human evidence for IV NAD+ in addiction is limited to uncontrolled clinic case series with no control group and no randomization ³⁴, the basic pharmacokinetics are weaker than the pitch implies ⁶, and even oral NAD+ precursors with real trials struggle to convert raised NAD+ into outcomes ⁷⁸. Meanwhile, there are genuinely evidence-based treatments for alcohol and opioid use disorder that reduce relapse and save lives ⁹¹⁰¹¹.

Treat NAD+ IV therapy as an expensive, unproven adjunct at most — never as a replacement for medication-assisted treatment, counseling, and proper medical supervision. (The same overselling shows up in the adjacent mental-health market, where drips are marketed for mood — see NAD+ IV therapy for depression and anxiety for why that evidence is just as weak.) If you want to understand the wider NAD+ picture, start with our NAD+ therapy evidence pillar, see the route-specific reality in NAD+ IV therapy evidence, and check how products and providers compare on our NAD+ rankings hub. For addiction itself, talk to a physician or an addiction-medicine specialist first.